Home/Filings/4/0000947871-21-000712
4//SEC Filing

OrbiMed Israel GP Ltd. 4

Accession 0000947871-21-000712

CIK 0001551986other

Filed

Jun 24, 8:00 PM ET

Accepted

Jun 25, 7:08 PM ET

Size

12.5 KB

Accession

0000947871-21-000712

Insider Transaction Report

Form 4
Period: 2021-06-23
OrbiMed Israel GP Ltd.
Director10% Owner
Transactions
  • Sale

    Common Stock

    2021-06-24$1.38/sh319,255$440,57224,555,850 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2021-06-25$1.21/sh15,989,876$19,347,7508,565,974 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2021-06-23$1.36/sh841,650$1,144,64424,875,105 total(indirect: See Footnotes)
Holdings
  • Common Stock

    (indirect: See Footnotes)
    31,944
Transactions
  • Sale

    Common Stock

    2021-06-25$1.21/sh15,989,876$19,347,7508,565,974 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2021-06-23$1.36/sh841,650$1,144,64424,875,105 total(indirect: See Footnotes)
  • Sale

    Common Stock

    2021-06-24$1.38/sh319,255$440,57224,555,850 total(indirect: See Footnotes)
Holdings
  • Common Stock

    (indirect: See Footnotes)
    31,944
Footnotes (3)
  • [F1]These shares of the Issuer's common stock are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund.
  • [F2]These shares of the Issuer's common stock are held of record by Nissim Darvish ("Darvish"). Pursuant to an agreement with OrbiMed BioFund and OrbiMed Israel GP, Darvish is obligated to transfer these securities, or the economic benefit thereof, to OrbiMed BioFund and OrbiMed Israel GP, which will in turn ensure that such securities or economic benefits are provided to OIP.
  • [F3]This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons and Darvish disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including the Reporting Persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Documents

1 file

Issuer

9 METERS BIOPHARMA, INC.

CIK 0001551986

Entity typeother
IncorporatedIsrael

Related Parties

1
  • filerCIK 0001569590

Filing Metadata

Form type
4
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 7:08 PM ET
Size
12.5 KB